Jupiter Topco LLC Takes Position in Intellia Therapeutics, Inc. $NTLA

Jupiter Topco LLC acquired a new position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 47,957 shares of the company’s stock, valued at approximately $812,000.

A number of other hedge funds have also modified their holdings of NTLA. AQR Capital Management LLC raised its position in shares of Intellia Therapeutics by 154.1% during the first quarter. AQR Capital Management LLC now owns 90,875 shares of the company’s stock worth $646,000 after purchasing an additional 55,118 shares during the period. Woodline Partners LP purchased a new stake in shares of Intellia Therapeutics during the first quarter valued at $171,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Intellia Therapeutics by 8.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company’s stock valued at $3,709,000 after purchasing an additional 38,521 shares during the period. Creative Planning increased its stake in Intellia Therapeutics by 12.9% in the 2nd quarter. Creative Planning now owns 33,102 shares of the company’s stock worth $310,000 after purchasing an additional 3,795 shares in the last quarter. Finally, Cetera Investment Advisers increased its stake in Intellia Therapeutics by 47.4% in the 2nd quarter. Cetera Investment Advisers now owns 33,532 shares of the company’s stock worth $315,000 after purchasing an additional 10,785 shares in the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Intellia Therapeutics Stock Performance

Shares of NASDAQ NTLA opened at $12.74 on Monday. Intellia Therapeutics, Inc. has a one year low of $7.95 and a one year high of $28.25. The business has a 50-day moving average price of $12.94 and a two-hundred day moving average price of $13.41. The firm has a market capitalization of $1.79 billion, a PE ratio of -3.79 and a beta of 1.82.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.80). The company had revenue of $7.66 million for the quarter, compared to the consensus estimate of $12.98 million. Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%.The firm’s quarterly revenue was down 46.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.98) EPS. Research analysts anticipate that Intellia Therapeutics, Inc. will post -3.21 EPS for the current year.

Insider Buying and Selling

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,641 shares of Intellia Therapeutics stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $16.78, for a total transaction of $44,315.98. Following the completion of the sale, the chief accounting officer owned 66,886 shares of the company’s stock, valued at $1,122,347.08. This trade represents a 3.80% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Edward J. Dulac III sold 4,677 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total transaction of $84,186.00. Following the transaction, the executive vice president owned 156,286 shares in the company, valued at approximately $2,813,148. This represents a 2.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 3.50% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on NTLA. New Street Research set a $25.00 price objective on shares of Intellia Therapeutics in a research note on Monday, June 15th. Wall Street Zen lowered shares of Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Citizens Jmp restated a “market outperform” rating and issued a $30.00 price target on shares of Intellia Therapeutics in a research report on Tuesday, August 25th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $49.00 price objective on shares of Intellia Therapeutics in a research note on Tuesday, June 16th. Finally, Wedbush lifted their price objective on shares of Intellia Therapeutics from $12.00 to $17.00 and gave the stock a “neutral” rating in a research report on Friday, July 10th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, eight have issued a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $21.15.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.